Shanghai North Carolina Jointly Builds Dongto Pharmaceutical Ecological Circle
Release time:
2020-07-22
Shanghai North Carolina Hand-in-Hand Medicine Finance Circle
Jointly Builds East to Medicine Ecology Circle
News 3# October 26 On the afternoon of the afternoon of the 12th, the "2019 East to Medicine Industry Development Forum" jointly sponsored by Medicine Finance Circle and Shanghai North Carolina Medicine Technology Co., Ltd. was held in Dongzhi County, Anhui Province, 40 More than pharmaceutical industry entrepreneurs gathered together to provide advice and suggestions for the future development of the pharmaceutical industry in Dongzhi County.
Pharmaceutical Finance Circle is an industry organization with certain influence in the domestic biomedical field. It brings together high-end pharmaceutical industry elites and biomedical companies, and is committed to building a pharmaceutical industry ecosystem. The concept of "sharing" solves common key issues such as projects, capital, and talents in the development of biomedicine, and forms a new ecology in the enterprise service field. "2019 East to Pharmaceutical Industry Development Forum" is an important part of the "Anhui Business Tour" organized by Shanghai North Carolina and Pharmaceutical Finance Circle. On the morning of
, the delegation visited Xinbeika Chemical, Zhongwang Pharmaceutical and other enterprises. Lou Xiaohua, executive deputy general manager of North Carolina Company, introduced the current development status of the company, the complete equipment and facilities and standardized management of the two companies, and the business philosophy of technological innovation as the core and "concentration, conscience, and anti-tumor leader" as its own responsibility. It was unanimously affirmed by the members of the delegation. Before the official start of the
forum, Huang Jinlong, deputy general manager of the group company and general manager of Jianfeng pharmaceutical, delivered a speech on behalf of Jianfeng group, thanking the county party Committee and county government for their support to the "dongzhilong pharmaceutical development forum", welcoming all the entrepreneurs present, briefly introducing why Jianfeng group chose to invest in dongzhilong, and inviting all colleagues to join in the development of dongzhilong pharmaceutical.
During the academic exchange, Kang Litao, the general manager of Shanghai North Carolina Company, gave a special report entitled "Deep Cultivation of Chemistry, Focusing on the Small Molecule Drug Manufacturing Platform of Medicine", which briefly introduced the development process and industry orientation of Shanghai North Carolina and the basic situation of Anhui New North Carolina Chemical and Anhui Zhongwang two production bases, it also focused on the function, research direction and future development plan of Jianfeng North Carolina Small Molecule Targeted Pharmaceutical Research Institute, made special exchanges with participating entrepreneurs, and sent them an invitation to work together for a win-win situation. In the event of
, the participating entrepreneurs fully discussed the current situation and future development trend of the pharmaceutical industry, and how to use their respective resources to cooperate and complement each other, and reached a number of intentional cooperation. (Zeng Xiaoyun Zhang Fuzhen)
More information
Publicity of Environmental Protection Acceptance for Completion of Kiln End Flue Gas Desulfurization Project of daye peak cement co., ltd. According to the requirements of the Interim Measures for Environmental Protection Acceptance for Completion of Construction Projects (No.4 [2017] of the State Environmental Regulations) issued by the Ministry of Environmental Protection, the environmental protection acceptance information of "Kiln End Flue Gas Desulfurization Project" of daye peak cement co., ltd. is now publicized. Basic Information of 1. Project Project Name: Kiln End Flue Gas Desulfurization Project Construction Unit: daye Jianfeng Cement Co., Ltd. Project Construction Location: Yongguang Village, Baoan Town, daye city, nature of the project in the existing plant area of daye Jianfeng Cement Co., Ltd.: The construction content of the technological transformation project is: This technological transformation project is mainly to build a wet desulfurization system for kiln end gas of the company's existing 4000t cement clinker production line, adopting limestone-gypsum wet flue gas desulfurization process. The project covers a total area of 500 m2, with a new construction area of about 450 m2. It mainly builds desulfurization complex building, flue gas system, SO2 absorption system, limestone powder conveying and limestone slurry preparation system, process water system, gypsum dehydration system and supporting pipelines. Power supply, water supply, compressed air and other public works rely on the existing plant. Total investment and environmental protection investment: the total investment of the project is 10.37 million yuan, all of which are environmental protection investment. The project was entrusted to Huangshi Yangtze River Environmental Engineering Design and Research Institute to carry out environmental impact assessment in September 2017. On November 16, 2017, Daye Municipal Environmental Protection Bureau issued a reply with YEHAN [2017] No. 354. Implementation of 2. environmental protection measures The scope of this acceptance is the flue gas desulfurization system and supporting facilities at the end of the kiln. (1) Exhaust gas pollution
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Contact Us
No. 88 Wujiang East Road, Jinhua City, Zhejiang Province, China
Tel: +86-579-82326868
Fax : +86-579-82324666
©2023 Zhejiang Jianfeng Group Co., Ltd. Powered by: www.300.cn SEO Business License
SAF Coolest v1.2 设置面板 SHJSS-AHDB-FSSQE-ZSW
无数据提示
Sorry, the current column has no content !
You can view other columns or return to Home Page